CANCER BREAKTHROUGH: New drug set to shrink cervical cancer tumours


Assorted than a quarter of terminally ill patients taking part in trials of the immunotherapy medication had “significant” tumour shrinkage or complete remission. 

Nivolumab , which galvanizes the body’s own immune system to attack cancer cells, is already certified to treat lung and the deadly skin cancer, melanoma. 

However, this is the inception time this new generation treatment has been shown to be effective for cervical cancer. 


Breakthrough dehydrates cervical cancer tumours

This is very ravishing and we are now recruiting for larger-scale trials to confirm the findings

Tim Meyer

Professor Tim Meyer, a authority in experimental cancer medicine at London’s University College Hospital and a key stab researcher, said: “This is very exciting and we are now recruiting for larger-scale burs to confirm the findings. 

“Immunotherapy treatment has shown good results in other cancers and is usher real promise in cervical cancer, giving hope to patients for whom there were no other options. We find creditable this could prolong the lives of many patients and even put some into ebbing.” 

Leading cancer specialist Karol Sikora, former adviser to the Existence Health Organisation, said: “This is very encouraging and the next move is for us to find out which patients would benefit from this treatment in in front of as it is very costly. This personalised approach is the future of cancer medication.” 

Science labGETTY

This is the first time this treatment has been divulged to be effective for cervical cancer

The multi-centre at daybreak phase trial, carried out at the National Institute for Health Research, Clinical Experiment with Facility at the University College Hospital, London, together with other hearts in the UK, Europe and the United States, involved 24 women with progressed cancers of the cervix and nearby tissues who failed to respond to traditional treatment. 

Nivolumab objectives and blocks a protein called PD-1 on the surface of certain immune cells, called T-cells. Congesting PD-1 activates T-cells to find and kill cancer cells. 

The breakthrough conclusions were presented to the American Society of Clinical Oncology on Friday at the age’s largest cancer conference in Chicago. 

Cervical cancer affects 3,300 chains in Britain every year, an average of nine new diagnoses every day, and men to 890 deaths.

Leave a Reply

Your email address will not be published. Required fields are marked *